Although it is well established that the circadian clock regulates mammalian reproductive physiology, the molecular mechanisms by which this regulation occurs are not clear. The authors investigated the reproductive capacity of mice lacking Bmal1 (Arntl, Mop3), one of the central circadian clock genes. They found that both male and female Bmal1 knockout (KO) mice are infertile. Gross and microscopic inspection of the reproductive anatomy of both sexes suggested deficiencies in steroidogenesis. Male Bmal1 KO mice had low testosterone and high luteinizing hormone serum concentrations, suggesting a defect in testicular Leydig cells. Importantly, Leydig cells rhythmically express BMAL1 protein, suggesting peripheral control of testosterone production by this clock protein. Expression of steroidogenic genes was reduced in testes and other steroidogenic tissues of Bmal1 KO mice. In particular, expression of the steroidogenic acute regulatory protein (StAR) gene and protein, which regulates the rate-limiting step of steroidogenesis, was decreased in testes from Bmal1 KO mice. A direct effect of BMAL1 on StAR expression in Leydig cells was indicated by in vitro experiments showing enhancement of StAR transcription by BMAL1. Other hormonal defects in male Bmal1 KO mice suggest that BMAL1 also has functions in reproductive physiology outside of the testis. These results enhance understanding of how the circadian clock regulates reproduction.Keywords circadian rhythms; fertility; testosterone; testes; sperm; StAR; mice Disruption of circadian rhythms results in a variety of pathophysiologic states (Hastings et al., 2003). Reproductive physiology, in particular, is profoundly influenced by circadian rhythms (Boden and Kennaway, 2006). In various insect species, the circadian clock is necessary for proper ovulation, sperm production, and fertility (Giebultowicz et al., 1989;Beaver et al., 2002;Beaver et al., 2003;Beaver and Giebultowicz, 2004 (Lucas and Eleftheriou, 1980;Clair et al., 1985;Chappell et al., 2003;Miller et al., 2004). For example, the surge of luteinizing hormone (LH) necessary for ovulation in rodents, which occurs at the same time of day during each estrous cycle, requires a functional circadian clock (Barbacka-Surowiak et al., 2003). In addition, at the onset of puberty, a clear diurnal rhythm of gonadotropin serum levels is established in both mice and humans (Andrews and Ojeda, 1981;Jean-Faucher et al., 1986;Dunkel et al., 1992;Apter et al., 1993). It is unclear whether this diurnal rhythm continues into adulthood, but testosterone serum concentration shows daily oscillations in adult male mice and humans (Lucas and Eleftheriou, 1980;Clair et al., 1985). Although the association between circadian rhythms and testosterone is a long-established phenomenon, the molecular mechanisms by which the circadian clock regulates testosterone production are unknown.The circadian clock is based on a transcription translation feedback loop that results in the cyclic expression of genes and proteins over a 24-h p...

Immunotherapies have emerged as one of the most promising approaches to treat patients with cancer. Recently, there have been many clinical successes using checkpoint receptor blockade, including T cell inhibitory receptors such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death-1 (PD-1). Despite demonstrated successes in a variety of malignancies, responses only typically occur in a minority of patients in any given histology. Additionally, treatment is associated with inflammatory toxicity and high cost. Therefore, determining which patients would derive clinical benefit from immunotherapy is a compelling clinical question.Although numerous candidate biomarkers have been described, there are currently three FDA-approved assays based on PD-1 ligand expression (PD-L1) that have been clinically validated to identify patients who are more likely to benefit from a single-agent anti-PD-1/PD-L1 therapy. Because of the complexity of the immune response and tumor biology, it is unlikely that a single biomarker will be sufficient to predict clinical outcomes in response to immune-targeted therapy. Rather, the integration of multiple tumor and immune response parameters, such as protein expression, genomics, and transcriptomics, may be necessary for accurate prediction of clinical benefit. Before a candidate biomarker and/or new technology can be used in a clinical setting, several steps are necessary to demonstrate its clinical validity. Although regulatory guidelines provide general roadmaps for the validation process, their applicability to biomarkers in the cancer immunotherapy field is somewhat limited. Thus, Working Group 1 (WG1) of the Society for Immunotherapy of Cancer (SITC) Immune Biomarkers Task Force convened to address this need. In this two volume series, we discuss pre-analytical and analytical (Volume I) as well as clinical and regulatory (Volume II) aspects of the validation process as applied to predictive biomarkers for cancer immunotherapy. To illustrate the requirements for validation, we discuss examples of biomarker assays that have shown preliminary evidence of an association with clinical benefit from immunotherapeutic interventions. The scope includes only those assays and technologies that have established a certain level of validation for clinical use (fit-for-purpose). Recommendations to meet challenges and strategies to guide the choice of analytical and clinical validation design for specific assays are also provided.Electronic supplementary materialThe online version of this article (doi:10.1186/s40425-016-0178-1) contains supplementary material, which is available to authorized users.

No abstract

The central circadian clock in mammals is housed in the brain and is based on cyclic transcription and translation of clock proteins. How the central clock regulates peripheral organ function is unclear. However, cyclic expression of circadian genes in peripheral tissues is well established, suggesting that these tissues have their own endogenous oscillators. Reproduction is a process influenced by circadian rhythms in many organisms, thus making the testis an attractive model for studying clock function in peripheral organs. However, results addressing cyclic expression of clock genes in the mammalian testis are inconsistent. To resolve this issue, RNA was extracted from testes of mice at various times of day. Expression of the circadian clock genes mPer1, mPer2, Bmal1, Clock, mCry1, and Npas2 was constant at all times. Immunohistochemical localization of mPER1 and CLOCK proteins revealed restricted expression only in cells at specific developmental stages of spermatogenesis. For mPER1, these stages are the spermatogonia and the condensing spermatids. In contrast, CLOCK expression was restricted to round spermatids, specifically within the developing acrosome. Expression of mPER1 and CLOCK was constant at all times of day. These results suggest that clock proteins have noncircadian functions in spermatogenesis. Noncircadian expression of clock genes was also found in the thymus, which, like the testis, is composed primarily of differentiating cells. We propose that cyclic expression of clock genes is suspended during cellular differentiation.

We recently generated and characterized transgenic mice in which regulatory sequences from a myosin light chain gene (MLC1f/3f) are linked to the chloramphenicol acetyltransferase (CAT) gene. Transgene expression in these mice is specific to skeletal muscle and graded along the rostrocaudal axis: adult muscles derived from successively more caudal somites express successively higher levels of CAT. To investigate the cellular basis of these patterns of expression, we developed and used a histochemical stain that allows detection of CAT in individual cells. Our main results are as follows: (a) Within muscles, CAT is detected only in muscle fibers and not in associated connective tissue, blood vessels, or nerves. Thus, the tissue specificity of transgene expression observed by biochemical assay reflects a cell-type specificity demonstrable histochemically. (b) Within individual muscles, CAT levels vary with fiber type. Like the endogenous MLC1f/3f gene, the transgene is expressed at higher levels in fast-twitch (type II) than in slow-twitch (type I) muscle fibers. In addition, CAT levels vary among type II fiber subtypes, in the order IIB greater than IIX greater than IIA. (c) Among muscles that are similar in fiber type composition, the average level of CAT per fiber varies with rostrocaudal position. This position-dependent variation in CAT level is apparent even when fibers of a single type are compared. From these results, we conclude that fiber type and position affect CAT expression independently. We therefore infer the existence of separate fiber type-specific and positionally graded transcriptional regulators that act together to determine levels of transgene expression.